Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mechanistic deconvolution reveals DHODH as the key target of the KDM4 inhibitor QC6352 [RNA-Seq]

ABSTRACT: The small molecule QC6352, developed as an inhibitor of the histone demethylase KDM4, exhibits potent anti-cancer activity, and its derivative, zavondemstat, is currently being evaluated in cancer clinical trials. Here, we demonstrate that the anti-proliferative efficacy of QC6352 in glioblastoma models is independent of KDM4 inhibition. Transcriptomic analysis revealed that QC6352's gene expression signature in glioblastoma cells closely resembles that of drugs targeting dihydroorotate dehydrogenase (DHODH). Biochemical assays, protein crystallography, metabolomic analysis, and uridine rescue experiments confirmed that QC6352 inhibits DHODH and thereby disrupts the de novo pyrimidine biosynthesis pathway. Furthermore, we show that the therapeutic efficacy of zavondemstat is primarily driven by DHODH inhibition, rather than KDM4 inhibition. Lastly, by uncovering the mechanism of action of QC6352, we identify PRMT5 inhibitors as synergistic partners for DHODH inhibitors, providing the basis for maximising the therapeutic impact of DHODH inhibitors in cancer treatments.

ORGANISM(S): Homo sapiens

PROVIDER: GSE292934 | GEO | 2026/03/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	GSE292934_raw_gene_counts.txt.gz	Txt

Items per page:

1 - 2 of 2

Similar Datasets

Mechanistic deconvolution reveals DHODH as the key target of the KDM4 inhibitor QC6352

Project description:The small molecule QC6352, developed as an inhibitor of the histone demethylase KDM4, exhibits potent anti-cancer activity, and its derivative, zavondemstat, is currently being evaluated in cancer clinical trials. Here, we demonstrate that the anti-proliferative efficacy of QC6352 in glioblastoma models is independent of KDM4 inhibition. Transcriptomic analysis revealed that QC6352's gene expression signature in glioblastoma cells closely resembles that of drugs targeting dihydroorotate dehydrogenase (DHODH). Biochemical assays, protein crystallography, metabolomic analysis, and uridine rescue experiments confirmed that QC6352 inhibits DHODH and thereby disrupts the de novo pyrimidine biosynthesis pathway. Furthermore, we show that the therapeutic efficacy of zavondemstat is primarily driven by DHODH inhibition, rather than KDM4 inhibition. Lastly, by uncovering the mechanism of action of QC6352, we identify PRMT5 inhibitors as synergistic partners for DHODH inhibitors, providing the basis for maximising the therapeutic impact of DHODH inhibitors in cancer treatments.

2026-03-31 | GSE296933 | GEO

Understanding the impact of KDM4 inhibition on host cell processes

Project description:HepG2-NTCP cells were cultured in 1% oxygen or treated with a KDM4 inhibitor, QC6352, for 72 hours. RNA was extracted and the impact of treatment on the cellular transcriptome was investigated by RNA-sequencing.

2024-01-31 | GSE186279 | GEO

Embryonic renal tumor cells sensitive to the small molecule inhibitor QC6352 display depletion of KDM4 levels and disruption of ribosome biogenesis-associated pathways

Project description:To investigate the effects of the KDM4 inhibitor QC6352 on embryonic renal tumor cells, we treated WiT49 anaplastic Wilms tumor cells and tumor-forming HEK293 human embryonic kidney cells with 25 nM QC6352 for 72 hours

2023-08-01 | GSE226112 | GEO

Expression data from KDM4 inhibition

Project description:Expression data from KDM4 inhibition

| PRJNA665064 | ENA

Transcriptional study of ARN8 cells treated with novel DHODH inhibitors

Project description:We have previously observed protein level changes after treating human cells with two novel inhibitors of the enzyme DHODH. This study was designed to study up to what degree these protein differences can be also observed at level of mRNA. As part of the de novo pyrimidine synthesis pathway, DHODH inhibition is expected to decrease the levels of total RNA in cells. However, some effector proteins associated with the p53 pathway are increased after treatment with these inhibitors. This study aims to answer if the observed protein differences are based on an increased transcription or due to protein stabilization.

2018-03-21 | GSE87577 | GEO

KDM4 inhibition targets breast cancer stem cells

Project description:Cancer progression is associated with alterations of epigenetic regulators such as histone-lysine demethylases 4 (KDM4)2-5. During breast cancer therapy, classical treatments fail to address resistant cancer stem cell populations6-10. Here, we identified a novel KDM4 inhibitor (KDM4(i)) with unique preclinical characteristics. KDM4(i) is a highly potent pan KDM4 inhibitor that specifically blocks the demethylase activity of KDM4A, B, C, and D but not that of the other members of the KDM family. We validated the KDM4(i) anti-tumoral properties under conditions recapitulating patient tumors. Therefore, we established a method to isolate and grow triple-negative breast cancer stem cells (BCSCs) from individual patient tumors after neoadjuvant chemotherapy. Limiting dilution orthotopic xenografts of these BCSCs faithfully regenerate original patient tumor histology and gene expression. KDM4(i) blocks proliferation, sphere formation and xenograft tumor growth of BCSCs. Importantly, KDM4(i) abrogates expression of EGFR, a driver of therapy-resistant triple-negative breast tumor cells11, via inhibition of the KDM4A demethylase activity. Taken together, we present a unique BCSC culture system as a basis for therapeutic compound identification and demonstrate that KDM4 inhibition is a new therapeutic strategy for the treatment of triple-negative breast cancer.

2018-04-10 | GSE95042 | GEO

KDM4 inhibition disrupts the core regulatory transcriptional circuitry in MYCN-driven neuroblastoma [ATAC-seq]

Project description:A small set of interconnected lineage-specific transcription factors (TFs) form a core regulatory circuitry (CRC) that establishes and maintains cell identity and grants selective dependencies of distinct cancer types. However, effective therapies to targeting CRC TFs remain lacking. Here, we show that the best-in-class KDM4 inhibitor QC6352 has a potent anticancer activity in MYCN-driven high-risk neuroblastoma and significantly represses the CRC TFs including MYCN, HAND2, ASCL1, PHOX2B by disrupting the super-enhancers that dominate the expression of CRC TFs. Furthermore, we have developed a combination therapy by integrating QC6352 into cytotoxic chemotherapy, which leads to a complete response of MYCN amplified tumors and a better animal survival. This study reveals that targeting histone lysine demethylase 4 family may transform into a therapeutic strategy in clinic for cancers driven by CRC TFs.

2024-03-04 | GSE164450 | GEO

KDM4 inhibition disrupts the core regulatory transcriptional circuitry in MYCN-driven neuroblastoma [RNA-seq]

2024-03-04 | GSE164455 | GEO

KDM4 inhibition disrupts the core regulatory transcriptional circuitry in MYCN-driven neuroblastoma [ChIP-seq]

2024-03-04 | GSE164451 | GEO

KDM4 inhibition disrupts the core regulatory transcriptional circuitry in MYCN-driven neuroblastoma [Cut&Tag]

2024-03-04 | GSE164454 | GEO